1. Pink Sheet

UK Price Scheme Changes To Cost Pharmaceutical Industry £33m

 
• By Ian Schofield

The government is expecting to reap UK-wide savings of £33m by basing the statutory drug pricing scheme on regular payments on sales rather than price cuts and limiting the maximum prices companies can charge the NHS. The move will bring the scheme more into line with the voluntary PPRS.

Coins
The UK NHS is expected to reap savings from changes to the statutory pricing scheme

New UK regulations coming into force on April 1 are expected to produce savings of £33m on the UK drugs bill by changing the way that the statutory drug pricing scheme works. Instead of being based on price cuts, it will now involve regular company percentage payments based on sales to the National Health Service, bringing it into line with the voluntary Pharmaceutical Price Regulation Scheme.

The statutory scheme applies to pharmaceutical companies that supply branded drugs to the NHS but are not part of the...

More from Pricing Debate

More from Market Access

Pharma’s Protests Fall Flat As UK Locks In High Rebate Rates

 
• By Neena Brizmohun

Despite pushback by industry, the government is standing by its new statutory scheme rebate rates for branded medicines, including one that doubles the rate that companies must repay on the sales of newer products to the National Health Service to 31.3%.

Argentina Speeds Up Market Access Process

 
• By Francesca Bruce

Companies operating in Argentina may get their medicines to the market more quickly thanks to new updates to the medicines authorization system.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.